Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323 + BNT327 in advanced breast cancer
CTR20251249Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab pamirtecan, pumitamig in breast cancer, sponsored by AbbVie Inc.. Started Jun 2025; status: active.
02
Drugs
trastuzumab pamirtecanpumitamig
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251249.